ERBB2 and diffuse midline glioma: Furthermore, in order to determine the toxicity in the pediatric population, a loco-regional phase 1 clinical trial at Seattle Children’s Hospital evaluated the repetitive dosing of HER2-specific CAR-T cells in patients with recurrent/refractory central nervous system (CNS) tumors, including diffuse midline glioma [33].